These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 38395940)

  • 1. "Take services to the people": strategies to optimize uptake of PrEP and harm reduction services among people who inject drugs in Uganda.
    Kamusiime B; Beima-Sofie K; Chhun N; Nalumansi A; Nalukwago GK; Kasiita V; Twesige CC; Kansiime R; Muwonge TR; Kyambadde P; Kadama H; Mudiope P; Glick S; Lambdin B; Mujugira A; Heffron R
    Addict Sci Clin Pract; 2024 Feb; 19(1):13. PubMed ID: 38395940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A qualitative study of service engagement and unmet needs among unstably housed people who inject drugs in Massachusetts.
    Hassan R; Roland KB; Hernandez B; Goldman L; Evans KN; Gaul Z; Agnew-Brune C; Buchacz K; Fukuda HD
    J Subst Abuse Treat; 2022 Jul; 138():108722. PubMed ID: 35067399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited Knowledge and Mixed Interest in Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs.
    Bazzi AR; Biancarelli DL; Childs E; Drainoni ML; Edeza A; Salhaney P; Mimiaga MJ; Biello KB
    AIDS Patient Care STDS; 2018 Dec; 32(12):529-537. PubMed ID: 30311777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical Providers and Harm Reduction Views on Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs.
    Hershow RB; Gonzalez M; Costenbader E; Zule W; Golin C; Brinkley-Rubinstein L
    AIDS Educ Prev; 2019 Aug; 31(4):363-379. PubMed ID: 31361517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs.
    Biello KB; Bazzi AR; Mimiaga MJ; Biancarelli DL; Edeza A; Salhaney P; Childs E; Drainoni ML
    Harm Reduct J; 2018 Nov; 15(1):55. PubMed ID: 30419926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-Exposure Prophylaxis Barriers, Facilitators and Unmet Need Among Rural People Who Inject Drugs: A Qualitative Examination of Syringe Service Program Client Perspectives.
    Surratt HL; Yeager HJ; Adu A; González EA; Nelson EO; Walker T
    Front Psychiatry; 2022; 13():905314. PubMed ID: 35706473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "We want everything in a one-stop shop": acceptability and feasibility of PrEP and buprenorphine implementation with mobile syringe services for Black people who inject drugs.
    Bartholomew TS; Andraka-Cristou B; Totaram RK; Harris S; Doblecki-Lewis S; Ostrer L; Serota DP; Forrest DW; Chueng TA; Suarez E; Tookes HE
    Harm Reduct J; 2022 Dec; 19(1):133. PubMed ID: 36463183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services.
    Bartholomew TS; Plesons M; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; Chueng TA; Ciraldo K; Brooks J; Smith JD; Barocas JA; Tookes HE
    Addict Sci Clin Pract; 2024 Mar; 19(1):21. PubMed ID: 38528570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. M
    Martel-Laferrière V; Feaster DJ; Metsch LR; Schackman BR; Loignon C; Nosyk B; Tookes H; Behrends CN; Arruda N; Adigun O; Goyer ME; Kolber MA; Mary JF; Rodriguez AE; Yanez IG; Pan Y; Khemiri R; Gooden L; Sako A; Bruneau J
    Trials; 2022 Apr; 23(1):341. PubMed ID: 35461260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs.
    Allen ST; Grieb SM; O'Rourke A; Yoder R; Planchet E; White RH; Sherman SG
    Harm Reduct J; 2019 May; 16(1):33. PubMed ID: 31109339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient and Provider Perspectives on a Novel, Low-Threshold HIV PrEP Program for People Who Inject Drugs Experiencing Homelessness.
    Bazzi AR; Shaw LC; Biello KB; Vahey S; Brody JK
    J Gen Intern Med; 2023 Mar; 38(4):913-921. PubMed ID: 35614171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of the COVID-19 pandemic on people who inject drugs accessing harm reduction services in an rural American state.
    Thakarar K; Kohut M; Hutchinson R; Bell R; Loeb HE; Burris D; Fairfield KM
    Harm Reduct J; 2022 Jul; 19(1):80. PubMed ID: 35869523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access to and acceptability of sexual and reproductive health, harm reduction and other essential health services among people who inject drugs in Durban, South Africa.
    Milford C; Cavanagh T; Bosman S; Wilson M; Smit J; Zanoni B
    Harm Reduct J; 2024 Jun; 21(1):123. PubMed ID: 38926755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivering integrated strategies from a mobile unit to address the intertwining epidemics of HIV and addiction in people who inject drugs: the HPTN 094 randomized controlled trial protocol (the INTEGRA Study).
    Goodman-Meza D; Shoptaw S; Hanscom B; Smith LR; Andrew P; Kuo I; Lake JE; Metzger D; Morrison EAB; Cummings M; Fogel JM; Richardson P; Harris J; Heitner J; Stansfield S; El-Bassel N;
    Trials; 2024 Feb; 25(1):124. PubMed ID: 38360750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuing Low Awareness and Use of Pre-exposure Prophylaxis (PrEP) for HIV among People Who Inject Drugs (PWID), San Francisco, 2022.
    Suprasert B; Tate M; Reagan D; Ruiz R; Gao K; McNaughton K; Miller K; Marr A; Taylor KD; Wilson EC; McFarland W
    AIDS Behav; 2024 Jun; 28(6):2089-2100. PubMed ID: 38526638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-exposure prophylaxis (PrEP) for HIV prevention among people who inject drugs: a global mapping of service delivery.
    Shaw G; Schaefer R; Schmidt HA; Madden A; Chang J; Mozalevskis A; Msimanga-Radebe B; Mangadan Konath N; Verster A; Baggaley R; Rodolph M; Macdonald V
    Harm Reduct J; 2023 Feb; 20(1):16. PubMed ID: 36782321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.
    McKellar MS; Des Marais AC; Chen H; Choi Y; Lilly R; Ayers D; Bennett J; Kestner L; Perry B; Poley S; Corneli A; Meade CS; Sachdeva N
    Harm Reduct J; 2024 Mar; 21(1):69. PubMed ID: 38532395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation.
    Corneli A; Perry B; Des Marais A; Choi Y; Chen H; Lilly R; Ayers D; Bennett J; Kestner L; Meade CS; Sachdeva N; McKellar MS
    Harm Reduct J; 2022 Dec; 19(1):132. PubMed ID: 36463214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Missed opportunities for healthcare providers to discuss HIV preexposure prophylaxis with people who inject drugs.
    Vincent W; McFarland W
    Int J Drug Policy; 2022 Dec; 110():103873. PubMed ID: 36252292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of an inner city HIV pre-exposure prophylaxis service tailored to the needs of people who inject drugs.
    Grimshaw C; Boyd L; Smith M; Estcourt CS; Metcalfe R
    HIV Med; 2021 Nov; 22(10):965-970. PubMed ID: 34585494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.